{"entity":{"id":"nct07150247","kind":"trial","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of iparomlimab and tuvonralimab, bevacizumab (glioblastoma use), fluorouracil (5-FU) and fOLFIRI (5-FU, leucovorin, irinotecan) in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07150247 by Sun Yat-sen University, with a registry enrolment figure of 20 participants, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Iparomlimab and Tuvonralimab; Bevacizumab; 5-Fluorouracil; Irinotecan (drug). Conditions listed: BRAF V600 Colorectal Cancer. Primary outcome: Objective Response Rate. Colorectal eligibility wording from the registry: \"* Histologically confirmed metastatic colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07150247","url":"https://clinicaltrials.gov/study/NCT07150247"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","braf-v600e-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["iparomlimab-tuvonralimab","bevacizumab-glioma","fluorouracil","folfiri"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07150247","phase":"2","setting":"A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","sponsor":"Sun Yat-sen University","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07150247/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}